Thursday, march 25 (healthday news) -- xifaxan has been approved for people with advanced liver disease to reduce the risk of overt hepatic encephalopathy (he), a reduction in brain function that occurs among people whose livers can't remove poisons from the blood, the us food and drug administration said in a news release. Xifaxan liver treatment. Background hepatic encephalopathy is a chronically debilitating complication of hepatic cirrhosis the efficacy of rifaximin, a minimally absorbed antibiotic, is well documented in the treatment of.
xifaxan liver treatment
Xifaxan (rifaximin) is an antibiotic indicated for the treatment of patients 12 years of age and older with travelers' diarrhea caused by noninvasive strains of escherichia coli (e coli), and to lower the risk of worsened brain function, or hepatic encephalopathy, in adults with liver failure. Rifaximin for hepatic encephalopathy is an antibiotic that’s usually used to treat traveler’s diarrhea and ibs. it’s also been approved by the us fda to help prevent he. this medicine is often taken twice daily to achieve this goal. is it safe to use?. Indications. xifaxan
0 comments:
Post a Comment